Loading
IARC estimates 1,072 new cancer cases and 697 cancer deaths in Djibouti in 2024; the commonest new cancers are breast, cervix uteri and prostate. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Djibouti's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 255 | 44.6 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 80 | 15.3 | Cervical cancer |
| Prostate | 73 | 19.1 | Prostate cancer |
| Colorectum | 68 | 6.7 | Colorectal cancer |
| Liver and intrahepatic bile ducts | 54 | 5.8 | Hepatocellular carcinoma |
| Non-Hodgkin lymphoma | 51 | 5.0 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 49 | 4.8 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Oesophagus | 33 | 3.5 | Oesophageal cancer |
| Trachea, bronchus and lung | 27 | 2.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Ovary | 27 | 5.2 | Ovarian cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Breast | 120 | 21.6 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Liver and intrahepatic bile ducts | 54 | 5.8 | Hepatocellular carcinoma |
| Cervix uteri | 50 | 9.5 | Cervical cancer |
| Prostate | 46 | 12.1 | Prostate cancer |
| Leukaemia | 41 | 4.0 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Colorectum | 36 | 3.7 | Colorectal cancer |
| Oesophagus | 33 | 3.5 | Oesophageal cancer |
| Non-Hodgkin lymphoma | 26 | 2.7 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Trachea, bronchus and lung | 23 | 2.4 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Ovary | 20 | 3.9 | Ovarian cancer |
No trial record in OnCo lists a site in Djibouti. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Djibouti.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Djibouti is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Djibouti is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.